Clinical Trials Logo

Hepatitis A clinical trials

View clinical trials related to Hepatitis A.

Filter by:

NCT ID: NCT00697931 Completed - Hepatitis B Clinical Trials

Immunogenicity and Reactogenicity of MPL Adjuvanted Recombinant Hepatitis B- Vaccine and Engerix™-B in Adult Non-Responders

Start date: May 1997
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the immunogenicity and reactogenicity of the adjuvanted recombinant hepatitis B vaccine with that of Engerix™-B when both are injected according to a three dose schedule (0, 1, 6 months) in an adult non-responder population

NCT ID: NCT00697853 Completed - Hepatitis B Clinical Trials

Immunogenicity and Safety of GSK Biologicals' HBV-MPL Vaccine (2 Doses), and of Engerix™-B (3 Doses) in Healthy Adults

Start date: November 1998
Phase: Phase 2
Study type: Interventional

This study is undertaken to assess the immune response and safety profile of 4 lots of the novel adjuvanted hepatitis B vaccine that were formulated following different processes, with Engerix™-B as the control vaccine

NCT ID: NCT00697840 Completed - Hepatitis B Clinical Trials

Safety, Immunogenicity and Reactogenicity of Recombinant Hepatitis B Vaccine (Adjuvanted & New Formulation) and Engerix™-B

Start date: June 1995
Phase: Phase 3
Study type: Interventional

The purpose of the present trial is to assess the safety, reactogenicity and immunogenicity of adjuvanted hepatitis B vaccine, Engerix™-B and hepatitis B vaccine new formulation when administered at 0, 6 months

NCT ID: NCT00697749 Completed - Hepatitis B Clinical Trials

Immunogenicity and Safety of a Novel Adjuvanted HBV Vaccine in Healthy Volunteers Positive for the HLA-DQ2 Genotype

Start date: April 1999
Phase: Phase 3
Study type: Interventional

This study compares the immunogenicity and safety of the novel adjuvanted HBV vaccine and Engerix™-B administered to subjects who were positively identified as having the HLA-DQ2 genotype

NCT ID: NCT00697242 Completed - Hepatitis B Clinical Trials

Comparison of Immuno, Reacto and Safety of Recombinant Hepatitis B Vaccine With or Without MPL in Healthy Older Adults

Start date: January 1994
Phase: Phase 3
Study type: Interventional

In the present study the immunogenicity, reactogenicity and safety of recombinant hepatitis B vaccines with and without MPL will be evaluated in older healthy subjects

NCT ID: NCT00697229 Completed - Hepatitis B Clinical Trials

Immunogenicity & Reactogenicity of HBV-MPL Vaccine and Engerix™-B in Healthy Adults Following 2 Different Schedules

Start date: September 1992
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety, immunogenicity and reactogenicity of MPL-adjuvanted recombinant hepatitis B vaccine in comparison with those of Engerix™-B in healthy adult volunteers following two different schedules: 0, 2 months and 0, 6 months

NCT ID: NCT00697125 Completed - Hepatitis B Clinical Trials

Immunogenicity & Reactogenicity of Various Formulations of Recombinant Hepatitis B Vaccine With Different Adjuvants

Start date: June 1993
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the immunogenicity and reactogenicity of various formulations of recombinant hepatitis B vaccine with different adjuvants in healthy adult volunteers following the 0, 1, 6 months schedule

NCT ID: NCT00696917 Completed - Hepatitis B Clinical Trials

Safety and Immunogenicity of 3 Lots of GSK Biologicals' HBV-MPL Vaccine and Engerix™-B in Healthy Volunteers ≥ 15y

Start date: April 1999
Phase: Phase 3
Study type: Interventional

This study was conducted to evaluate the lot-to-lot consistency of three lots of HBV-MPL vaccine and to compare their safety and immunogenicity with that of Engerix™-B.

NCT ID: NCT00695019 Completed - Clinical trials for Hepatitis C, Chronic

Interferon-alpha Lozenges for Prevention of Relapse in Hepatitis C

Start date: June 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether lozenges of interferon-alpha that are dissolved in the mouth can prevent relapse in patients with hepatitis C virus infection who had a complete virologic response after receiving a combination of injected interferon-alpha and oral ribavirin.

NCT ID: NCT00689546 Recruiting - Diabetes Mellitus Clinical Trials

Acute Viral Hepatitis and Diabetes Mellitus

Start date: February 2007
Phase: N/A
Study type: Observational

It has been observed that several of patients having prolonged or complicated course of acute viral hepatitis have underlying diabetes. It is possible that with impaired hepatocyte regenerating capacity, these patients run a more prolonged and complicated course. We hypothesize that acute hepatitis infection has a prolonged and complicated course among diabetic patients.